Royalty Pharma (NASDAQ:RPRX – Get Free Report) and Nexentis Technologies (NASDAQ:NXTS – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.
Analyst Ratings
This is a summary of recent ratings and price targets for Royalty Pharma and Nexentis Technologies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Royalty Pharma | 0 | 0 | 8 | 0 | 3.00 |
| Nexentis Technologies | 1 | 0 | 0 | 0 | 1.00 |
Royalty Pharma currently has a consensus target price of $61.57, indicating a potential downside of 3.17%. Given Royalty Pharma’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Royalty Pharma is more favorable than Nexentis Technologies.
Insider and Institutional Ownership
54.3% of Royalty Pharma shares are owned by institutional investors. Comparatively, 61.2% of Nexentis Technologies shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by insiders. Comparatively, 6.5% of Nexentis Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk & Volatility
Royalty Pharma has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Nexentis Technologies has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500.
Profitability
This table compares Royalty Pharma and Nexentis Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Royalty Pharma | 32.14% | 30.01% | 14.91% |
| Nexentis Technologies | N/A | -304.79% | -178.91% |
Valuation and Earnings
This table compares Royalty Pharma and Nexentis Technologies”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Royalty Pharma | $2.38 billion | 15.38 | $770.95 million | $1.45 | 43.86 |
| Nexentis Technologies | $210,000.00 | 3.62 | -$4.00 million | ($96.07) | -0.01 |
Royalty Pharma has higher revenue and earnings than Nexentis Technologies. Nexentis Technologies is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Royalty Pharma beats Nexentis Technologies on 12 of the 14 factors compared between the two stocks.
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
About Nexentis Technologies
N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
